The Latest Breaking News from Decibel

"These were songs that I took with me to that first band – didn’t get a chance to get them out in my second band – but my third one I did”

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry anticipated to thrive, fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR) look poised for substantial gains. Keep reading.

Decibel Cannabis Company Inc. (OTCQB: DBCCF) (TSXV:DB) has appointed Manjit Minhas, an entrepreneur, venture capitalist and beer baroness as a senior advisor to its board of directors until the company's upcoming annual shareholder meeting whe

Decibel Cannabis Company Inc. (NYSE: DB) (OTC: DBCCF) has provided an operational update with respect to its capital projects and announced its fourth consecutive month of record market share in February.

Marijuana producer Decibel Cannabis Company Inc. (TSXV:DB) (OTCQB: DBCCF) provided an update on its recent Canadian recreational market share.

Decibel Therapeutics Inc (NASDAQ: DBTX) announced the presentation of preclinical data on DB-OTO, its lead gene therapy product candidate.

Cannabis producer Decibel Cannabis Company Inc. (TSXV: DB) (OTCQB: DBCCF),  has closed its previously announced financing with connectFirst Credit Union Ltd. in respect of $54 million of debt capital over an initial 5-year term.

Decibel Cannabis Company Inc. (TSX-V: DB) (OTCQB: DBCCF) provided an update on its strategic priorities and 2022 financial outlook.

Decibel Cannabis Company Inc. (TSX-V: DB) (OTCQB: DBCCF) reported Thursday that it has granted, effective after market close on Jan. 19, 2022, some of 3.47 million stock options to certain officers and employees of the company in accordance with its stock option plan.